2 completed, 2 terminated, 1 recruiting, 1 withdrawn. 4 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 4 | 1 | Withdrawn 1 |
Follow Endoglin: new trials by email Literature Review of Endoglin trials Research Report on Endoglin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors Cohort 1 Intervention group, Cohort 2 severe/CIS margins clear, Cohort 2 p53 and severe/CIS margins clear - Oral Epithelial Dysplasia (OED), Oral Squamous Cell Carcinoma (SCC) | Not applicable | Recruiting | University of British Columbia | 636 | 2026-07-08 | 2026-09-08 |
| Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) Etonogestrel (ENG) Subdermal Implants - HIV-1-infection | Phase 4 | Withdrawn | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2024-01-01 | 2024-12-13 | |
| A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) Radiopaque Etonogestrel (ENG) Implant - Contraception | Phase 3 | Completed | Organon and Co | 498 | 2020-11-19 | 2026-02-18 |
| Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059) Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring, Placebo vaginal ring, Ibuprofen - Moderate to Severe Primary Dysmenorrhea | Phase 3 | Terminated | Organon and Co | 25 | 2016-02-11 | 2024-05-28 |
| Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060) ENG 125 μg + E2 300 μg vaginal ring (MK-8342B), Placebo vaginal ring, Ibuprofen - Dysmenorrhea | Phase 3 | Terminated | Organon and Co | 18 | 2016-02-09 | 2024-05-28 |
| A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) ENG 120 µg + EE 15 µg intravaginal ring, DRSP 3 mg + EE 30 µg - Contraception | Phase 3 | Completed | Organon and Co | 983 | 2011-09-19 | 2024-06-20 |
Dysmenorrhea (1) · Squamous Cell Carcinoma of Head and Neck (1)
Organon and Co (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · University of British Columbia (1)
Canada (1) · Puerto Rico (1) · United States (1)
2015 (2), UM1AI068636 (1)